[Glial migration inhibition test in multiple sclerosis patients and its changes during treatment with immunosuppressants].
Results of examining the blood serum of 90 patients with disseminated sclerosis, 94 patients with other nervous diseases, and 20 healthy subjects using the glia migration inhibition test are presented. It is shown that the index of the glia migration inhibition (IGMI) gets higher during exacerbation of the disseminated sclerosis and drops in cases of relative stabilization of the clinical manifestations and remission. In the course of treatment with immunodepressants, such as, prednisolone (alone, or in combination with cyclophosphan) and antilymphocytic immunoglobulin, the IGMI falls down. Possible use of the IGMI for determining the indications for the immunodepressant therapy and for solving differential diagnostic and therapy control problems is discussed.
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002464:Cell Migration Inhibition; D003520:Cyclophosphamide / Q000627:therapeutic use; D003937:Diagnosis, Differential; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000097:blood* / Q000628:therapy; D009457:Neuroglia / Q000276:immunology*; D011239:Prednisolone / Q000627:therapeutic use
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011239:Prednisolone
Test tormozheniia migratsii glii u bol'nykh rasseiannym sklerozom i ego dinamika pri lechenii immunodepressantami.